Search results
WHO report shows sexually transmitted infections are climbing
Center for Infectious Disease Research and Policy· 3 days agoA new report from the World Health Organization (WHO) shows that 2 years into a global effort to...
TREMFYA® (guselkumab) QUASAR Maintenance Study in UC met its primary endpoint and all major...
FOX 23 News Albany· 6 days agoWASHINGTON, May 20, 2024 /PRNewswire/ -- Johnson & Johnson today announced the first data from the Phase 3 QUASAR Maintenance Study (Abstract #759) that showed 50.0 percent (p<0.001) of patients ...
Word of the Day: Don't Say "Covid Pandemic." Say "Covid Syndemic"! | naked capitalism
Naked Capitalism· 6 days ago"'Tis a mystery," except not!
ADA2 regulates inflammation and hematopoietic stem cell emergence via the A2bR pathway in zebrafish...
Nature· 4 days agoA DADA2 zebrafish model with cecr1b deficiency was generated. Characterization of hematopoietic processes revealed a role of Cecr1b in regulating inflammation and hematopoietic stem cell production through the A2br-mediated adenosine signaling.
ZYMFENTRA™ (infliximab-dyyb) demonstrated long-term efficacy and safety profile of maintenance...
FOX 59 Indianapolis· 5 days agoCelltrion USA announced today positive two-year results from the extended LIBERTY studies (LIBERTY-CD and LIBERTY-UC) for ZYMFENTRA™ (infliximab-dyyb) in adult patients with moderately to severely ...
UCB Announces Publication in The Lancet of Phase 3 BIMZELX® (bimekizumab-bkzx) Trials in...
KTLA-TV Los Angeles· 3 days agoUCB, a global biopharmaceutical company, today announced that The Lancet has published results from the Phase 3 BE HEARD I and BE HEARD II trials evaluating the efficacy and safety of BIMZELX ...